PRGO: Perrigo Company plc Stock

by  •  • Comments Off on PRGO: Perrigo Company plc Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 4,131.88
Enterprise Value ($M) 7,453.98
Book Value ($M) 4,767.90
Book Value / Share 35.18
Price / Book 0.87
NCAV ($M) -3,208.30
NCAV / Share -23.67
Price / NCAV -1.29

Profitability (mra)
Return on Invested Capital (ROIC) -0.00
Return on Assets (ROA) -0.00
Return on Equity (ROE) -0.00

Liquidity (mrq)
Quick Ratio 1.07
Current Ratio 1.79

Balance Sheet (mrq) ($M)
Current Assets 2,832.90
Assets 10,809.10
Liabilities 6,041.20
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 4,655.60
Operating Income 284.50
Net Income -12.70
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 405.50
Cash from Investing -77.50
Cash from Financing -187.20

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G Barrow Hanley Mewhinney & Strauss Llc
02-13 13G/A Vanguard Group Inc 11.07 2.77
01-24 13G/A BlackRock Inc. 9.80 0.92

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended: September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended: July 1, 2023 ☐ TRANSITION REPORT PURSUANT TO SE
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended: April 1, 2023 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-24 164,410 818,505 20.09
2024-04-23 231,073 839,768 27.52
2024-04-22 149,701 1,208,847 12.38
2024-04-19 104,647 1,168,219 8.96

(click for more detail)

Similar Companies
OGN – Organon & Co. PBH – Prestige Consumer Healthcare Inc.
PFE – Pfizer Inc. QGEN – Qiagen N.V.
RCUS – Arcus Biosciences, Inc.


Financial data and stock pages provided by
Fintel.io